Jane C Burns Selected Research

Intravenous Immunoglobulins (IVIG)

1/2022	Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C.
1/2022	Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
1/2022	Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
12/2021	Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
10/2021	Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C.
1/2019	Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
1/2019	The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
12/2018	Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
12/2018	Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease.
1/2018	Whole blood transcriptional profiles as a prognostic tool in complete and incomplete Kawasaki Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jane C Burns Research Topics

Disease

88	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 03/2022 - 02/2003
30	Aneurysm (Aneurysms) 01/2022 - 01/2007
22	Inflammation (Inflammations) 01/2022 - 05/2009
17	Fever (Fevers) 12/2021 - 10/2004
10	Vasculitis (Vasculitides) 01/2022 - 08/2004
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 06/2005
6	COVID-19 03/2022 - 08/2021
6	Heart Diseases (Heart Disease) 03/2019 - 10/2004
5	Infections 01/2019 - 01/2014
4	COVID-19 related pediatric multisystem inflammatory disease 06/2022 - 01/2020
4	Thrombosis (Thrombus) 01/2021 - 11/2014
4	Rheumatic Fever (Acute Articular Rheumatism) 01/2008 - 06/2005
4	Endocarditis 01/2008 - 06/2005
3	Fibrosis (Cirrhosis) 10/2021 - 12/2015
3	Virus Diseases (Viral Diseases) 11/2020 - 01/2016
3	Bacteremia 01/2008 - 06/2007
2	Myocarditis (Carditis) 10/2022 - 01/2021
2	Autoimmune Diseases (Autoimmune Disease) 03/2022 - 01/2022
2	Thrombocytopenia (Thrombopenia) 01/2022 - 08/2021
2	Cytokine Release Syndrome 01/2022 - 08/2021
2	Communicable Diseases (Infectious Diseases) 01/2022 - 06/2005
2	Shock 01/2020 - 05/2009
2	Pathologic Constriction (Stenosis) 04/2016 - 04/2016
2	Myocardial Infarction 04/2016 - 01/2016
2	Heart Failure 04/2016 - 12/2015
2	Disease Susceptibility (Diathesis) 01/2013 - 02/2011
2	Disease Progression 01/2013 - 09/2012
1	Pneumonia (Pneumonitis) 03/2022
1	Common Cold 01/2022
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2022
1	Gastritis 01/2022
1	Macrophage Activation Syndrome 01/2022
1	Lung Diseases (Lung Disease) 01/2022
1	Giant Cell Arteritis (Horton Disease) 01/2022
1	Hemolytic Anemia 12/2021
1	Asthma (Bronchial Asthma) 10/2021
1	Hypersensitivity (Allergy) 10/2021

Drug/Important Bio-Agent (IBA)

44	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 02/2003
12	Infliximab (Remicade)FDA Link 01/2022 - 05/2005
12	Biomarkers (Surrogate Marker)IBA 10/2021 - 05/2009
9	Peptides (Polypeptides)IBA 06/2022 - 12/2010
7	Proteins (Proteins, Gene)FDA Link 03/2022 - 12/2011
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 10/2004
6	AntibodiesIBA 01/2022 - 01/2011
5	Immunoglobulin G (IgG)IBA 01/2021 - 01/2013
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2015 - 02/2003
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 10/2004
4	Anti-Bacterial Agents (Antibiotics)IBA 08/2016 - 06/2007
4	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2015 - 02/2011
3	AntigensIBA 03/2022 - 01/2022
3	Interleukin-1 (Interleukin 1)IBA 01/2022 - 09/2010
3	Pharmaceutical PreparationsIBA 01/2022 - 12/2008
3	C-Reactive ProteinIBA 01/2021 - 05/2009
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 07/2008
3	Monoclonal AntibodiesIBA 12/2018 - 05/2005
3	CalciumIBA 10/2017 - 03/2012
3	Blood Proteins (Serum Proteins)IBA 01/2016 - 12/2010
3	AnticoagulantsIBA 11/2014 - 10/2004
3	VaccinesIBA 01/2008 - 06/2007
3	gamma-Globulins (gamma-Globulin)IBA 05/2005 - 10/2004
2	Neutralizing AntibodiesIBA 10/2022 - 01/2022
2	AutoantigensIBA 03/2022 - 01/2022
2	Interleukin-15 (Interleukin 15)IBA 01/2022 - 08/2021
2	CytokinesIBA 01/2022 - 08/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2022
2	Formaldehyde (Formol)FDA Link 01/2022 - 08/2021
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2022 - 01/2016
2	SteroidsIBA 01/2020 - 09/2006
2	Atorvastatin (Lipitor)FDA Link 12/2019 - 01/2015
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019 - 09/2012
2	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2013
2	RNA (Ribonucleic Acid)IBA 08/2016 - 01/2013
2	Phenobarbital (Luminal)FDA Link 04/2016 - 07/2015
2	Lipoproteins (Lipoprotein)IBA 01/2016 - 10/2014
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016 - 01/2013
2	Immunoglobulins (Immunoglobulin)IBA 12/2015 - 05/2005
2	Matrix Metalloproteinases (MMPs)IBA 01/2014 - 12/2010
2	Abciximab (ReoPro)FDA Link 12/2004 - 10/2004
1	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 03/2022
1	AutoantibodiesIBA 01/2022
1	Interleukin-6 InhibitorsIBA 01/2022
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2022
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2022
1	Environmental Pollutants (Pollutants, Environmental)IBA 01/2022
1	Insulin (Novolin)FDA Link 01/2022
1	InterleukinsIBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	Adenosine Triphosphatases (ATPase)IBA 01/2022
1	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2021
1	CaspasesIBA 10/2021

Therapy/Procedure

31	Therapeutics 01/2022 - 08/2004
4	Anesthesia 01/2008 - 06/2005
3	Resuscitation 01/2021 - 01/2020
3	Endarterectomy (Thromboendarterectomy) 12/2017 - 07/2015
2	Artificial Respiration (Mechanical Ventilation) 01/2021 - 01/2020
2	Aftercare (After-Treatment) 12/2018 - 05/2005
2	Critical Care (Surgical Intensive Care) 08/2016 - 06/2005
2	Retreatment 12/2004 - 10/2004
2	Physical Therapy Modalities (Physical Therapy Technique) 12/2004 - 10/2004
1	Injections 01/2022